INVESTORS
Investor Overview
Corporate Profile
About Protara Therapeutics, Inc.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
Price
Change
Volume
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Press Releases
December 7, 2020
December 3, 2020
November 24, 2020
November 12, 2020
btn News
Events
December 3, 2020 at 12:10 PM EST
November 24, 2020
November 18, 2020 at 1:45 PM EST
btn Events
Presentations
IR Contact
Justine O’Malley
Vice President, Investor Relations and Communications
Phone: 646-817-2836
Email: Justine.OMalley@protaratx.com